Voyager Therapeutics (VYGR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 64.44%. A quarter ago, it was expected that this gene therapy company would post a loss of $0.38 per share when it actually produced a loss of $0.18, delivering a surprise of 52.63%.Over the last four quarters, the co ...

- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025 - - Recent third-party clinical data establish that an antibody can inhibit tau accumulation in the human brain; provide support for use of an antibody to target tau in Alzheimer’s - - Continued partnership progress in Q3 2024 evidenced by new capsid license and new gene therapy development candidate selection - - INDs on track for three CNS gene ...

LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET. A webcast of the presentation may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be a ...

Core Insights - Voyager Therapeutics, Inc. is participating in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase on August 14, 2024, at 9:30 a.m. ET [1] - The company focuses on advancing neurogenetic medicines aimed at treating neurological diseases [3] Company Overview - Voyager Therapeutics is dedicated to leveraging human genetics to modify and potentially cure neurological diseases, with a pipeline that includes programs for Alzheimer's disease, ALS, Parkinson's disease, and other central nervous system diseases [3] - The company utilizes its TRACER™ AAV capsid discovery platform to generate novel capsids for high brain penetration of genetic medicines following intravenous dosing [3] - Voyager has both wholly owned programs and collaborations with partners such as Alexion, AstraZeneca Rare Disease, Novartis Pharma AG, Neurocrine Biosciences, Inc., and Sangamo Therapeutics, Inc. [3]

分组1 - Voyager Therapeutics reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.38, and an improvement from a loss of $0.51 per share a year ago, resulting in an earnings surprise of 52.63% [1] - The company achieved revenues of $29.58 million for the quarter ended June 2024, exceeding the Zacks Consensus Estimate by 156.75%, compared to revenues of $4.85 million in the same quarter last year [2] - Voyager Therapeutics has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 5.6% since the beginning of the year, while the S&P 500 has gained 8.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $10.77 million, and for the current fiscal year, it is -$1.39 on revenues of $52.72 million [7] - The Medical - Biomedical and Genetics industry, to which Voyager Therapeutics belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the ...

The stock option award to Dr. Jorgensen provides for the purchase of an aggregate of 200,000 shares of Voyager's common stock, and the restricted stock unit award to Dr. Jorgensen will represent 80,000 shares of Voyager's common stock. The stock option has a ten-year term and an exercise price of $7.79 per share, which is equal to the closing price of Voyager's common stock on July 8, 2024, the effective date of grant. The stock option vests over four years, with 25% of the shares underlying the stock optio ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Trista Morrison - Chief Corporate Affairs Officer Alfred Sandrock - CEO Todd Carter - Chief Scientific Officer Toby Ferguson - Chief Medical Officer Robin Swartz - COO and Principal Financial Officer Conference Call Participants Mehdi Goudarzi - Truist Securities Jack Allen - Baird Patrick Trucchio - H.C. Wainwright & Co. Philip Nadeau - TD Cowen Ry Forseth - Guggenheim Securities David Hoa ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission file number: 001-37625 Voyager Therapeutics, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-30031 ...

EXHIBIT 99.1 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results – Company announces clearance of IND application with FDA for anti-tau antibody VY-TAU01 for the treatment of Alzheimer's disease; expect to begin single ascending dose trial in the coming weeks – – Development candidates selected for Neurocrine-partnered GBA1 and Friedreich's Ataxia gene therapy programs; potential for three gene therapies, including SOD1- ALS, to enter the clinic in 2025 – – Appointed neurology cl ...